ELATROLET

Pajjiż: Iżrael

Lingwa: Ingliż

Sors: Ministry of Health

Ixtrih issa

Ingredjent attiv:

AMITRIPTYLINE HYDROCHLORIDE

Disponibbli minn:

TEVA ISRAEL LTD

Kodiċi ATC:

N06AA09

Għamla farmaċewtika:

TABLETS

Kompożizzjoni:

AMITRIPTYLINE HYDROCHLORIDE 10 MG

Rotta amministrattiva:

PER OS

Tip ta 'preskrizzjoni:

Required

Manifatturat minn:

TEVA PHARMACEUTICAL INDUSTRIES LTD, ISRAEL

Żona terapewtika:

AMITRIPTYLINE

Indikazzjonijiet terapewtiċi:

For the relief of symptoms of depression. Endogenous depression is more likely to be alleviated than other depressive states. Enuresis nocturna.

Data ta 'l-awtorizzazzjoni:

2021-01-31

Fuljett ta 'informazzjoni

                                Amitriptyline-10mg-25mg-tabs-PIL-29C-KK-05-2022_
ENG-D11-F
Patient leaflet in accordance with the Pharmacists' Regulations
(Preparations) - 1986
This medicine is dispensed with a doctor’s prescription only
Elatrol
Tablets
Composition
Each tablet contains:
Amitriptyline Hydrochloride 25 mg
Elatrolet
Tablets
Composition
Each tablet contains:
Amitriptyline Hydrochloride 10 mg
For
information
about
inactive
ingredients
and
allergens,
see
section
2
under
‘Important information about some of this medicine’s
ingredients’ and section 6 -
‘Additional information’.
Read the entire leaflet carefully before you start using this
medicine. This leaflet
contains concise information about this medicine. If you have any
further questions,
consult your doctor or pharmacist.
This medicine has been prescribed to treat your illness. Do not pass
it on to others. It
may harm them, even if it seems to you that their illness is similar
to yours.
1.
What is this medicine intended for?
Medical activity
For the treatment of symptoms of depression and treatment of
bed-wetting at night
(enuresis nocturna).
Therapeutic group
Non-selective monoamine reuptake inhibitors (N06AA).
2.
Before using this medicine
Do not use this medicine if:

you are sensitive to the active ingredient or to any of the other
ingredients in
this medicine (see section 6 - ‘Additional information’)

you have recently had a heart attack (myocardial infarction)

you have any heart problems such as: disturbances in heart rhythm
which are
seen on an electrocardiogram (ECG), heart block, or coronary artery
disease

you are taking monoamine oxidase inhibitors (MAOIs)

you have taken MAOIs within the last 14 days

you have taken moclobemide the day before
Page 2 of 11
Elatrol-Elatrolet-PIL-notif-KK-05-2022_ENG-D11-F_clean-word

you have severe liver disease

you are treated with Elatrol/Elatrolet tablets, you have to stop
taking this
medicine and wait for 14 days before starting treatment with a MAOI.

you are below 12 years of age.
Sp
                                
                                Aqra d-dokument sħiħ
                                
                            

Dokumenti f'lingwi oħra

Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Għarbi 29-11-2022
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Ebrajk 08-06-2022

Fittex twissijiet relatati ma 'dan il-prodott

Ara l-istorja tad-dokumenti